title: Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome.
abstract: OBJECTIVE
  To evaluate the efficacy of ranibizumab in the treatment of choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
  
  
  METHODS
  Patients enrolled in the ranibizumab group received a monthly intravitreal injection of 0.5 mg of ranibizumab. Patients in the photodynamic therapy (PDT) group received a quarterly dosing of intravenous verteporfin coupled with PDT.
  
  
  RESULTS
  Mean change in ETDRS visual acuity at 1 year was 19.6 letters in the ranibizumab group versus 21 letters in the PDT group. All patients in the PDT group required rescue ranibizumab therapy. Four of five patients (80%) in the ranibizumab group and one of two patients (50%) in the PDT group showed a greater than 15 letter gain at 1 year.
  
  
  CONCLUSIONS
  Ranibizumab appears to be a safe and effective treatment option for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome.
authors: The Retina Institute, 1600 S. Brentwood Blvd., Suite 800, St. Louis, MO 63144, USA.
authors: Kamalesh J
authors: KJ
authors: Ramaiya
authors: Kevin J
authors: KJ
authors: Blinder
authors: Thomas
authors: T
authors: Ciulla
authors: Blake
authors: B
authors: Cooper
authors: Gaurav K
authors: GK
authors: Shah
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D005260:Female; D005451:Fluorescein Angiography; D006660:Histoplasmosis / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D007275:Injections, Intravenous; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D000069579:Ranibizumab; D013577:Syndrome; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000069579:Ranibizumab